Acro Biomedical , Ltd. Overview
Valuation check: ACBM's ROE is 31.57%, above the sector sector average of 11.73%.
Get informed when a big investor buys or sells
+ Follow31.57%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Acro Biomedical , Ltd.'s return on equity stands at 31.57%. That is above the sector sector average of 11.73%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Acro Biomedical , Ltd. sits higher the its sector benchmark (11.73%) with a ROE of 31.57%. That is roughly 169.0% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 31.57% for Acro Biomedical , Ltd. means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Acro Biomedical , Ltd.'s ROE evolved across reporting periods, while the comparison chart places ACBM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
